ZimVie has acquired ARCHIMED, a prominent healthcare-focused investment firm, for an undisclosed amount. The acquisition marks a significant strategic move for ZimVie in the dynamic healthcare sector.
ARCHIMED, with offices in Europe, North America, and APAC, specializes exclusively in healthcare industries. The firm provides a blend of operational, medical, scientific, and financial expertise to its partners. Its prioritized areas of focus span Biopharma Products, Consumer Health, Animal & Environmental Health, Healthcare IT, Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED actively supports its portfolio companies in internationalization, acquisitions, innovation, and product and service expansion. It manages €8 billion across various funds and is also recognized as a committed Impact investor through its EURÊKA Foundation.
This acquisition is strategically aimed at integrating ARCHIMED’s deep sector knowledge and extensive network into ZimVie. By acquiring ARCHIMED, ZimVie gains access to unparalleled insights into healthcare market trends, emerging technologies, and investment opportunities across a broad spectrum of healthcare sub-sectors. The synergies are expected to arise from leveraging ARCHIMED's specialized expertise to enhance ZimVie's strategic initiatives and market presence, potentially enabling more informed decision-making and accelerated growth within the healthcare industries.
The combined entity is anticipated to strengthen its footprint and influence within the global healthcare landscape. This integration is set to create a robust platform, poised to capitalize on future innovation and expansion opportunities across the diverse and evolving healthcare ecosystem.